Antibodies against human epidermal growth factor receptor 2 (HER2) have been approved for the treatment of HER2-positive breast cancer and they are used for companion diagnostic testing for targeted cancer therapies, as HER2-positive breast cancer is about 30% [46]. This evidence concerns the gene ERBB2 and breast cancer.